Inflammation and Performance Status: The Cornerstones of Prognosis in Advanced Cancer
In advanced cancer, although performance status (PS), systemic inflammatory response and nutritional status are known to have prognostic value, geographical variations and sociodemographic indexes may also impact survival. This study compares validated prognostic factors in two international cohorts...
Gespeichert in:
| Veröffentlicht in: | Journal of pain and symptom management 2023-04, Vol.65 (4), p.348-357 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 357 |
|---|---|
| container_issue | 4 |
| container_start_page | 348 |
| container_title | Journal of pain and symptom management |
| container_volume | 65 |
| creator | Rocha, Bruna M.M. Dolan, Ross D. Paiva, Carlos E. McGovern, Josh Paiva, Bianca S.R. Preto, Daniel D. McMillan, Donald C. Maia, Yara C.P. Laird, Barry J. |
| description | In advanced cancer, although performance status (PS), systemic inflammatory response and nutritional status are known to have prognostic value, geographical variations and sociodemographic indexes may also impact survival.
This study compares validated prognostic factors in two international cohorts and establishes a prognostic framework for treatment.
Two international biobanks of patients (n=1.518) with advanced cancer were analyzed. Prognostic factors (Eastern Cooperative Oncology Group Performance Status [ECOG-PS], body mass index [BMI] and modified Glasgow Prognostic Score [mGPS]) were assessed. The relationship between these and survival was examined using Kaplan–Meier and Cox regression methods.
According to multivariate analysis, in the European cohort the most highly predictive factors were BMI 28 kg/m2) to 44% (mGPS 2, BMI |
| doi_str_mv | 10.1016/j.jpainsymman.2022.11.021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2753298067</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0885392422010065</els_id><sourcerecordid>2753298067</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-45d2e4c28087255f8a1e6bb6a90acdfa2d86ee8ff33b34980a4bbfa7112815ef3</originalsourceid><addsrcrecordid>eNqNkMlOwzAURS0EoqXwC8js2CR4yOCwqyKGSpWoRLu2nOQZXDV2sdNK_XsStSCWrN7m3Hv1DkJ3lMSU0OxhHa-3ythwaFtlY0YYiymNCaNnaExFzqMspfwcjYkQacQLlozQVQhrQkjKM36JRjxLCl4IOkarmdUb1fd0xlmsbIMX4LXzfXEN-L1T3S484uUn4NJ5Cz50zkLATuOFdx_WBROwsXja7IdAg8vh-Gt0odUmwM3pTtDq-WlZvkbzt5dZOZ1HdcJEFyVpwyCpmSAiZ2mqhaKQVVWmCqLqRivWiAxAaM15xZNCEJVUlVY5pUzQFDSfoPtj79a7rx2ETrYm1LDZKAtuFyTLU876XJb3aHFEa-9C8KDl1ptW-YOkRA5W5Vr-sSoHq5JS2Vvts7enmV3VQvOb_NHYA-URgP7ZvQEvQ21gEGI81J1snPnHzDdDwI_X</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2753298067</pqid></control><display><type>article</type><title>Inflammation and Performance Status: The Cornerstones of Prognosis in Advanced Cancer</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Rocha, Bruna M.M. ; Dolan, Ross D. ; Paiva, Carlos E. ; McGovern, Josh ; Paiva, Bianca S.R. ; Preto, Daniel D. ; McMillan, Donald C. ; Maia, Yara C.P. ; Laird, Barry J.</creator><creatorcontrib>Rocha, Bruna M.M. ; Dolan, Ross D. ; Paiva, Carlos E. ; McGovern, Josh ; Paiva, Bianca S.R. ; Preto, Daniel D. ; McMillan, Donald C. ; Maia, Yara C.P. ; Laird, Barry J.</creatorcontrib><description>In advanced cancer, although performance status (PS), systemic inflammatory response and nutritional status are known to have prognostic value, geographical variations and sociodemographic indexes may also impact survival.
This study compares validated prognostic factors in two international cohorts and establishes a prognostic framework for treatment.
Two international biobanks of patients (n=1.518) with advanced cancer were analyzed. Prognostic factors (Eastern Cooperative Oncology Group Performance Status [ECOG-PS], body mass index [BMI] and modified Glasgow Prognostic Score [mGPS]) were assessed. The relationship between these and survival was examined using Kaplan–Meier and Cox regression methods.
According to multivariate analysis, in the European cohort the most highly predictive factors were BMI <20 kg/m2 (hazard ratio [HR] 1.644), BMI 20-21.9 kg/m2 (HR 1.347), ECOG-PS (HR 1.597–11.992) and mGPS (HR 1.843–2.365). In the Brazilian cohort, the most highly predictive factors were ECOG-PS (HR 1.678–8.938) and mGPS (HR 2.103–2.837). Considering gastrointestinal cancers in particular (n=551), the survival rate at 3 months in both cohorts together ranged from 93% (mGPS 0, PS 0–1) to 0% (mGPS 2, PS 4), and from 81% (mGPS 0, BMI >28 kg/m2) to 44% (mGPS 2, BMI <20 kg/m2).
The established prognostic factors that were compared had similar prognostic capacity in both cohorts. A high ECOG-PS and a high mGPS as outlined in the ECOG-PS/mGPS framework were consistently associated with poorer survival of patients with advanced cancer in the prospective European and Brazilian cohorts.</description><identifier>ISSN: 0885-3924</identifier><identifier>EISSN: 1873-6513</identifier><identifier>DOI: 10.1016/j.jpainsymman.2022.11.021</identifier><identifier>PMID: 36493981</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Advanced cancer ; Humans ; Inflammation ; Neoplasms - diagnosis ; Neoplasms - therapy ; performance status ; Prognosis ; Proportional Hazards Models ; Prospective Studies ; Retrospective Studies ; survival analysis</subject><ispartof>Journal of pain and symptom management, 2023-04, Vol.65 (4), p.348-357</ispartof><rights>2022 American Academy of Hospice and Palliative Medicine</rights><rights>Copyright © 2022 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-45d2e4c28087255f8a1e6bb6a90acdfa2d86ee8ff33b34980a4bbfa7112815ef3</citedby><cites>FETCH-LOGICAL-c428t-45d2e4c28087255f8a1e6bb6a90acdfa2d86ee8ff33b34980a4bbfa7112815ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jpainsymman.2022.11.021$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36493981$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rocha, Bruna M.M.</creatorcontrib><creatorcontrib>Dolan, Ross D.</creatorcontrib><creatorcontrib>Paiva, Carlos E.</creatorcontrib><creatorcontrib>McGovern, Josh</creatorcontrib><creatorcontrib>Paiva, Bianca S.R.</creatorcontrib><creatorcontrib>Preto, Daniel D.</creatorcontrib><creatorcontrib>McMillan, Donald C.</creatorcontrib><creatorcontrib>Maia, Yara C.P.</creatorcontrib><creatorcontrib>Laird, Barry J.</creatorcontrib><title>Inflammation and Performance Status: The Cornerstones of Prognosis in Advanced Cancer</title><title>Journal of pain and symptom management</title><addtitle>J Pain Symptom Manage</addtitle><description>In advanced cancer, although performance status (PS), systemic inflammatory response and nutritional status are known to have prognostic value, geographical variations and sociodemographic indexes may also impact survival.
This study compares validated prognostic factors in two international cohorts and establishes a prognostic framework for treatment.
Two international biobanks of patients (n=1.518) with advanced cancer were analyzed. Prognostic factors (Eastern Cooperative Oncology Group Performance Status [ECOG-PS], body mass index [BMI] and modified Glasgow Prognostic Score [mGPS]) were assessed. The relationship between these and survival was examined using Kaplan–Meier and Cox regression methods.
According to multivariate analysis, in the European cohort the most highly predictive factors were BMI <20 kg/m2 (hazard ratio [HR] 1.644), BMI 20-21.9 kg/m2 (HR 1.347), ECOG-PS (HR 1.597–11.992) and mGPS (HR 1.843–2.365). In the Brazilian cohort, the most highly predictive factors were ECOG-PS (HR 1.678–8.938) and mGPS (HR 2.103–2.837). Considering gastrointestinal cancers in particular (n=551), the survival rate at 3 months in both cohorts together ranged from 93% (mGPS 0, PS 0–1) to 0% (mGPS 2, PS 4), and from 81% (mGPS 0, BMI >28 kg/m2) to 44% (mGPS 2, BMI <20 kg/m2).
The established prognostic factors that were compared had similar prognostic capacity in both cohorts. A high ECOG-PS and a high mGPS as outlined in the ECOG-PS/mGPS framework were consistently associated with poorer survival of patients with advanced cancer in the prospective European and Brazilian cohorts.</description><subject>Advanced cancer</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Neoplasms - diagnosis</subject><subject>Neoplasms - therapy</subject><subject>performance status</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Prospective Studies</subject><subject>Retrospective Studies</subject><subject>survival analysis</subject><issn>0885-3924</issn><issn>1873-6513</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMlOwzAURS0EoqXwC8js2CR4yOCwqyKGSpWoRLu2nOQZXDV2sdNK_XsStSCWrN7m3Hv1DkJ3lMSU0OxhHa-3ythwaFtlY0YYiymNCaNnaExFzqMspfwcjYkQacQLlozQVQhrQkjKM36JRjxLCl4IOkarmdUb1fd0xlmsbIMX4LXzfXEN-L1T3S484uUn4NJ5Cz50zkLATuOFdx_WBROwsXja7IdAg8vh-Gt0odUmwM3pTtDq-WlZvkbzt5dZOZ1HdcJEFyVpwyCpmSAiZ2mqhaKQVVWmCqLqRivWiAxAaM15xZNCEJVUlVY5pUzQFDSfoPtj79a7rx2ETrYm1LDZKAtuFyTLU876XJb3aHFEa-9C8KDl1ptW-YOkRA5W5Vr-sSoHq5JS2Vvts7enmV3VQvOb_NHYA-URgP7ZvQEvQ21gEGI81J1snPnHzDdDwI_X</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Rocha, Bruna M.M.</creator><creator>Dolan, Ross D.</creator><creator>Paiva, Carlos E.</creator><creator>McGovern, Josh</creator><creator>Paiva, Bianca S.R.</creator><creator>Preto, Daniel D.</creator><creator>McMillan, Donald C.</creator><creator>Maia, Yara C.P.</creator><creator>Laird, Barry J.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202304</creationdate><title>Inflammation and Performance Status: The Cornerstones of Prognosis in Advanced Cancer</title><author>Rocha, Bruna M.M. ; Dolan, Ross D. ; Paiva, Carlos E. ; McGovern, Josh ; Paiva, Bianca S.R. ; Preto, Daniel D. ; McMillan, Donald C. ; Maia, Yara C.P. ; Laird, Barry J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-45d2e4c28087255f8a1e6bb6a90acdfa2d86ee8ff33b34980a4bbfa7112815ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Advanced cancer</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Neoplasms - diagnosis</topic><topic>Neoplasms - therapy</topic><topic>performance status</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Prospective Studies</topic><topic>Retrospective Studies</topic><topic>survival analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rocha, Bruna M.M.</creatorcontrib><creatorcontrib>Dolan, Ross D.</creatorcontrib><creatorcontrib>Paiva, Carlos E.</creatorcontrib><creatorcontrib>McGovern, Josh</creatorcontrib><creatorcontrib>Paiva, Bianca S.R.</creatorcontrib><creatorcontrib>Preto, Daniel D.</creatorcontrib><creatorcontrib>McMillan, Donald C.</creatorcontrib><creatorcontrib>Maia, Yara C.P.</creatorcontrib><creatorcontrib>Laird, Barry J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pain and symptom management</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rocha, Bruna M.M.</au><au>Dolan, Ross D.</au><au>Paiva, Carlos E.</au><au>McGovern, Josh</au><au>Paiva, Bianca S.R.</au><au>Preto, Daniel D.</au><au>McMillan, Donald C.</au><au>Maia, Yara C.P.</au><au>Laird, Barry J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inflammation and Performance Status: The Cornerstones of Prognosis in Advanced Cancer</atitle><jtitle>Journal of pain and symptom management</jtitle><addtitle>J Pain Symptom Manage</addtitle><date>2023-04</date><risdate>2023</risdate><volume>65</volume><issue>4</issue><spage>348</spage><epage>357</epage><pages>348-357</pages><issn>0885-3924</issn><eissn>1873-6513</eissn><abstract>In advanced cancer, although performance status (PS), systemic inflammatory response and nutritional status are known to have prognostic value, geographical variations and sociodemographic indexes may also impact survival.
This study compares validated prognostic factors in two international cohorts and establishes a prognostic framework for treatment.
Two international biobanks of patients (n=1.518) with advanced cancer were analyzed. Prognostic factors (Eastern Cooperative Oncology Group Performance Status [ECOG-PS], body mass index [BMI] and modified Glasgow Prognostic Score [mGPS]) were assessed. The relationship between these and survival was examined using Kaplan–Meier and Cox regression methods.
According to multivariate analysis, in the European cohort the most highly predictive factors were BMI <20 kg/m2 (hazard ratio [HR] 1.644), BMI 20-21.9 kg/m2 (HR 1.347), ECOG-PS (HR 1.597–11.992) and mGPS (HR 1.843–2.365). In the Brazilian cohort, the most highly predictive factors were ECOG-PS (HR 1.678–8.938) and mGPS (HR 2.103–2.837). Considering gastrointestinal cancers in particular (n=551), the survival rate at 3 months in both cohorts together ranged from 93% (mGPS 0, PS 0–1) to 0% (mGPS 2, PS 4), and from 81% (mGPS 0, BMI >28 kg/m2) to 44% (mGPS 2, BMI <20 kg/m2).
The established prognostic factors that were compared had similar prognostic capacity in both cohorts. A high ECOG-PS and a high mGPS as outlined in the ECOG-PS/mGPS framework were consistently associated with poorer survival of patients with advanced cancer in the prospective European and Brazilian cohorts.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36493981</pmid><doi>10.1016/j.jpainsymman.2022.11.021</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3924 |
| ispartof | Journal of pain and symptom management, 2023-04, Vol.65 (4), p.348-357 |
| issn | 0885-3924 1873-6513 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2753298067 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Advanced cancer Humans Inflammation Neoplasms - diagnosis Neoplasms - therapy performance status Prognosis Proportional Hazards Models Prospective Studies Retrospective Studies survival analysis |
| title | Inflammation and Performance Status: The Cornerstones of Prognosis in Advanced Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T01%3A42%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inflammation%20and%20Performance%20Status:%20The%20Cornerstones%20of%20Prognosis%20in%20Advanced%20Cancer&rft.jtitle=Journal%20of%20pain%20and%20symptom%20management&rft.au=Rocha,%20Bruna%20M.M.&rft.date=2023-04&rft.volume=65&rft.issue=4&rft.spage=348&rft.epage=357&rft.pages=348-357&rft.issn=0885-3924&rft.eissn=1873-6513&rft_id=info:doi/10.1016/j.jpainsymman.2022.11.021&rft_dat=%3Cproquest_cross%3E2753298067%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2753298067&rft_id=info:pmid/36493981&rft_els_id=S0885392422010065&rfr_iscdi=true |